The original antibody was isolated from peripheral blood B cells of an individual with chronic HCV genotype 1a infection who had a high serum antibody binding titer to E2 and high neutralizing activity (>1:10,000 titer) against genotype 1a HCVpp. The B cells were activated by Epstein-Barr virus and used to produce human hybridomas.
